NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access
Decision brief
Answer first · skim in under a minute
The National Medical Products Administration (NMPA) approved a record 61 drugs for first global approval in 2025, spanning modalities from small molecules to cell and gene therapies. New regulatory measures on contract manufacturing and pre-approval importation signal a more agile yet controlled approval environment for BD teams and investors.
NMPA's 2025 rulemaking—tighter contract-manufacturing oversight, a pathway for pre-approval commercial import batches, and reset export-certificate controls—matters as much for China market access as any year-end approval tally for business-development and supply-chain teams.
Contents10 sections
Key Takeaways
- Announcement No. 134 (2025) strengthens supervision of drug contract manufacturing for marketing authorization holders.
- Announcement No. 96 (2025) allows importation of pre-approval commercial-scale batches of overseas-marketed drugs to shorten the gap between approval and supply.
- Export-certificate administrative provisions (No. 113, 2025) take effect January 1, 2026 for manufacturers exporting pharmaceuticals.
- A peer-reviewed 2024 baseline counted 46 Class 1/1.1 innovative drug approvals—useful context, not a substitute for verified 2025 tallies from NMPA English primaries.
What contract-manufacturing rules did NMPA tighten?
NMPA published the Announcement on Strengthening Supervision and Administration of Contract Manufacturing of Drugs (No. 134, 2025) on its English site.
The measure targets quality and accountability when marketing authorization holders outsource production—an acute issue as China scales innovative modalities that rely on CDMOs.
For BD and diligence teams, No. 134 raises the cost of weak tech-transfer documentation and ambiguous quality agreements in China manufacturing networks.
How does Announcement No. 96 change launch sequencing?
The NMPA Announcement on Matters Concerning the Importation of Pre-approval Commercial-Scale Batch Products of Overseas-Marketed Drugs (No. 96, 2025) aims to let patients use overseas-marketed products sooner after China approval.
NMPA's accompanying policy interpretation frames the goal as shortening the time gap between approval and market supply for innovative and clinically urgent drugs.
Sponsors should remodel inventory and QP/release plans so commercial-scale overseas batches can enter China legally under No. 96 conditions rather than waiting for local commercial manufacture.
What export-certificate changes hit on January 1, 2026?
NMPA issued the Administrative Provisions on Inspection and Export Certificate for Pharmaceutical Products Exported by Pharmaceutical Manufacturers (No. 113, 2025), with materials dated December 24, 2025 and an effective date of January 1, 2026.
Exporters and China-based CMOs should update inspection readiness and certificate request workflows before shipping under the new provisions.
Multinational supply chains that treat China as an export hub need to map which SKUs require refreshed certificates under No. 113.
How should investors read 2025 approval-volume headlines?
Secondary tallies of "first global approvals" circulate widely, but English NMPA primaries cited here do not themselves publish a verified 61-count figure. We therefore do not treat that number as established in this rewrite.
For a sourced 2024 baseline, PubMed 40262297 reports NMPA approved 46 Class 1 or 1.1 innovative drugs in 2024.
Compare any 2025 volume claim against primary NMPA statistical releases before using it in investment models.
What should China BD and market-access teams do next?
Re-paper CDMO quality agreements against No. 134 expectations and document batch-release accountability.
Build No. 96 import scenarios into launch critical-path timelines for overseas-origin products seeking China labels.
Audit export-certificate inventories before January 2026 shipments under No. 113.
What remains unproven?
Headline approval counts without an NMPA English statistical primary remain unverified here and should not drive diligence alone.
Regulatory agility does not guarantee NRDL pricing outcomes or provincial tender wins.
Contract-manufacturing crackdowns can slow some launches even as import-batch rules accelerate others—net cycle-time effects are company-specific.
Related NovaPharma coverage
- Rusan Pharma PMDA approval coverage
- Global drug discovery market outlook
- Drug discovery technology market sizing
Frequently Asked Questions
What did NMPA Announcement No. 134 change?
Announcement No. 134 (2025) strengthens supervision and administration of contract manufacturing of drugs, increasing compliance expectations for MAHs that outsource production.
What is NMPA Announcement No. 96 about?
Announcement No. 96 (2025) sets rules for importing pre-approval commercial-scale batches of overseas-marketed drugs so patients can access product sooner after China approval.
When do the 2025 export-certificate provisions take effect?
NMPA's Administrative Provisions on Inspection and Export Certificate for Pharmaceutical Products Exported by Pharmaceutical Manufacturers (No. 113, 2025) were published with an effective date of January 1, 2026.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
